ATE293690T1 - USE OF CANCER-ASSOCIATED ANTIGEN 5T4 FOR IMMUNOTHERAPY - Google Patents

USE OF CANCER-ASSOCIATED ANTIGEN 5T4 FOR IMMUNOTHERAPY

Info

Publication number
ATE293690T1
ATE293690T1 AT99972219T AT99972219T ATE293690T1 AT E293690 T1 ATE293690 T1 AT E293690T1 AT 99972219 T AT99972219 T AT 99972219T AT 99972219 T AT99972219 T AT 99972219T AT E293690 T1 ATE293690 T1 AT E293690T1
Authority
AT
Austria
Prior art keywords
immunotherapy
associated antigen
cancer
taa
tumours
Prior art date
Application number
AT99972219T
Other languages
German (de)
Inventor
Miles William Carroll
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269555&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9825303.2A external-priority patent/GB9825303D0/en
Priority claimed from GBGB9901739.4A external-priority patent/GB9901739D0/en
Priority claimed from GBGB9917995.4A external-priority patent/GB9917995D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE293690T1 publication Critical patent/ATE293690T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.
AT99972219T 1998-11-18 1999-11-18 USE OF CANCER-ASSOCIATED ANTIGEN 5T4 FOR IMMUNOTHERAPY ATE293690T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9825303.2A GB9825303D0 (en) 1998-11-18 1998-11-18 Vector
GBGB9901739.4A GB9901739D0 (en) 1999-01-27 1999-01-27 Polypeptide
GBGB9917995.4A GB9917995D0 (en) 1999-07-30 1999-07-30 Polypeptide
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy

Publications (1)

Publication Number Publication Date
ATE293690T1 true ATE293690T1 (en) 2005-05-15

Family

ID=27269555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972219T ATE293690T1 (en) 1998-11-18 1999-11-18 USE OF CANCER-ASSOCIATED ANTIGEN 5T4 FOR IMMUNOTHERAPY

Country Status (10)

Country Link
EP (4) EP1152060B1 (en)
JP (1) JP4907767B2 (en)
KR (1) KR20010084935A (en)
CN (1) CN1298851C (en)
AT (1) ATE293690T1 (en)
AU (1) AU766954B2 (en)
CA (1) CA2351622A1 (en)
DE (1) DE69924826T8 (en)
GB (1) GB2347932B (en)
WO (1) WO2000029428A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
JP2003515323A (en) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド Body
DE60040555D1 (en) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd cules
US7402666B2 (en) 2000-11-13 2008-07-22 Oxford Biomedica (Uk) Ltd. Nucleotide encoding canine 5T4 antigen
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
DK1335987T4 (en) 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
CA2434546C (en) * 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
CN101397574A (en) 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 Flavivirus NS1 subunit vaccine
SI1504108T1 (en) 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviral vector
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
DE60314823T3 (en) 2002-04-19 2017-11-16 Bavarian Nordic A/S MODIFIED VARIANT OF VACCINIA ANKARA VIRUS AS VACCINE FOR NEWBORN
ATE393212T2 (en) 2002-09-05 2008-05-15 Bavarian Nordic As METHOD FOR AMPLIFICATION OF A POXVIRUS IN SERUM-FREE CONDITIONS
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
US7514533B2 (en) 2003-05-21 2009-04-07 Ares Trading S.A. TNF-like secreted protein
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
WO2006120473A2 (en) * 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Mhc class i and ii peptide antigens derived from tumour antigen 5t4
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
PA8718601A1 (en) 2006-03-10 2009-05-15 Wyeth Corp ANTI-5T4 ANTIBODIES AND THEIR USES
CA2665423A1 (en) 2006-10-12 2008-04-17 Wyeth Methods and compositions with reduced opalescence
DK2076592T3 (en) 2006-10-23 2017-07-24 Medical Res Council POLYMERASE
MX367851B (en) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates.
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2018235130B2 (en) 2017-03-15 2023-12-07 Oxford Biomedica (Uk) Limited Method
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (en) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド Pyrrolobenzodiazepine antibody conjugate
AU2019369340A1 (en) 2018-10-29 2021-05-20 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795954B2 (en) 1982-11-30 1995-10-18 アメリカ合衆国 Method for producing recombinant poxvirus for expression of foreign gene
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
ES2259177T3 (en) 1990-08-13 2006-09-16 Isis Pharmaceuticals, Inc. MODIFIED OLIGONUCLEOTIDES IN SUGAR THAT DETECT AND MODULATE GENE EXPRESSION.
WO1998004727A1 (en) * 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
JP2001517453A (en) 1997-09-23 2001-10-09 オックスフォード バイオメディカ（ユーケイ）リミテッド Method
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors

Also Published As

Publication number Publication date
AU1394900A (en) 2000-06-05
GB2347932A (en) 2000-09-20
GB0014986D0 (en) 2000-08-09
EP1036091B1 (en) 2005-04-20
AU766954B2 (en) 2003-10-30
JP4907767B2 (en) 2012-04-04
CA2351622A1 (en) 2000-05-25
EP1036091B2 (en) 2008-03-26
CN1333829A (en) 2002-01-30
KR20010084935A (en) 2001-09-07
EP2042598A1 (en) 2009-04-01
DE69924826D1 (en) 2005-05-25
DE69924826T2 (en) 2006-02-23
DE69924826T3 (en) 2008-05-29
EP1160323A1 (en) 2001-12-05
EP1152060B1 (en) 2015-04-15
WO2000029428A3 (en) 2000-11-09
EP1036091A1 (en) 2000-09-20
WO2000029428A2 (en) 2000-05-25
JP2002530060A (en) 2002-09-17
DE69924826T8 (en) 2008-09-25
GB2347932B (en) 2003-05-07
EP1152060A1 (en) 2001-11-07
CN1298851C (en) 2007-02-07

Similar Documents

Publication Publication Date Title
ATE293690T1 (en) USE OF CANCER-ASSOCIATED ANTIGEN 5T4 FOR IMMUNOTHERAPY
IL145813A0 (en) SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ1
MX339406B (en) Neisseria meningitidis antigens and compositions.
BR0010361A (en) Genetic sequences of neisseria and use of these
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
IL138075A0 (en) Vaccines, immunotherapeutics and methods for using the same
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
ATE347904T1 (en) CANCER IMMUNOTHERAPY AND CANCER DIAGNOSIS USING UNIVERSAL TUMOR-ASSOCIATED ANTIGENS INCLUDING HTERT
EP1536006A4 (en) Cancer antigens and utilization thereof
MXPA01008605A (en) Goodpasture antigen binding protein.
WO2003085087A3 (en) Modified cea nucleic acid and expression vectors
WO2021252620A3 (en) Dna encoded antibodies for use against sars-cov-2
IL156041A0 (en) Nucleic acid adjuvants
WO2004092212A3 (en) Tumor antigens bfa5 for prevention and/or treatment of cancer
EP0972054A4 (en) Enhancement of immune response using targeting molecules
WO2009083968A8 (en) Novel protein
WO2023192990A3 (en) Antibodies against human siglec-9 and use thereof for immunotherapy
DK1077720T3 (en) Preparation for Induction of a Tumor-Specific Immune Response, Method of Preparation and Use of the Preparation for the Treatment of Neoplasms
WO2005035773A8 (en) Modified cea /b7 vector
WO2007059030A3 (en) Llo-encoding dna/nucleic acid vaccines and methods comprising same
AU2002336244A1 (en) Trp2 isoform trp2-6b containing hla-a2-restricted epitopes
WO2005068640A3 (en) Modified ksa and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1036091

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1036091

Country of ref document: EP